DDInter133 DDInter1694
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Atorvastatin {u} (Compound) resembles {v} (Compound) Conivaptan
Atorvastatin {u} (Compound) treats {v} (Disease) coronary artery disease
Atorvastatin {u} (Compound) binds {v} (Gene) SLCO1B3
Atorvastatin {u} (Compound) upregulates {v} (Gene) PRKCD
Atorvastatin {u} (Compound) downregulates {v} (Gene) CCDC86
Atorvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Medroxyprogesterone acetate
Atorvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Atorvastatin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Atorvastatin (Compound) resembles Conivaptan (Compound)
Atorvastatin (Compound) treats coronary artery disease (Disease)
Atorvastatin (Compound) binds SLCO1B3 (Gene)
Atorvastatin (Compound) upregulates PRKCD (Gene)
Atorvastatin (Compound) downregulates CCDC86 (Gene)
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Atorvastatin may lead to a major life threatening interaction when taken with Leflunomide